ConvaTec stock gains as analysts keep moderate buy rating

Published on 09/03/2026 at 22:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec stock is trading above 2.30 pounds as of September 3, 2026, with analysts maintaining a moderate buy consensus and seeing upside from current levels.

Architektur-Rendering eines modernen Forschungs- und Entwicklungsgebäudes mit Glasfassade — ConvaTec Group Plc GB00BD3VFW73 zeigt architektonisches Render eines gläsernen Forschungs- und Entwicklungsgebäudes bei Tageslicht, Illustration mit AI erstellt.

ConvaTec Group stock (ISIN GB00BD3VFW73) is trading around 2.34 pounds per share as of September 3, 2026, keeping the medical products specialist in focus for investors watching UK healthcare names.

Analysts see upside from current levels

According to a consensus summary compiled by MarketBeat on September 3, 2026, ConvaTec Group carries an average analyst rating of moderate buy, supported by several positive assessments in recent months. One of the highlighted views is that Royal Bank Of Canada has reissued an outperform stance on the shares, with a price target of 315 GBX set in an earlier report, indicating room for appreciation from the current level of just above 230 GBX that was noted when the report was compiled.

Market data summarized by Simply Wall St shows ConvaTec Group trading at approximately 2.34 pounds per share in early September 2026, while an estimated fair value based on discounted future cash flows stands at about 4.28 pounds per share. This implies a valuation discount of about 45.4% relative to that intrinsic value estimate, underscoring why the stock is appearing on lists of UK value names that may be priced below their calculated worth.

Valuation and peer context in UK healthcare

In its September 2026 review of UK value opportunities, Simply Wall St points out that ConvaTec Group, at a share price near 2.336 pounds, trades significantly below its modeled fair value of 4.28 pounds. The gap of roughly 45.4% between the current market price and the fair value estimate is notable and places the company among UK-listed stocks that, by this metric, may offer value for long-term investors.

This valuation backdrop comes as broad-based European healthcare shares have shown resilience in 2026. A Swissquote morning note dated September 3, 2026 mentions that ConvaTec Group closed on a positive note alongside peers such as Fresnillo, Standard Chartered and HSBC Holdings, indicating that the stock participated in a generally constructive market session for London-listed names. For investors, the combination of a positive closing tone and a sizable discount to estimated intrinsic value creates a clear narrative: the market is willing to reward the shares in supportive sessions, but the longer-term valuation case suggests that sentiment has not yet fully caught up with cash flow expectations.

Go deeper

More on ConvaTec Group fundamentals and valuation

For a broader view of ConvaTec Group stock, including historical results and additional valuation metrics, the overview on ad-hoc-news.de and the company investor relations page offer further details.

ConvaTec news and price overview Investor Relations

ConvaTec products in advanced wound care

ConvaTec Group is best known for its medical devices and products in advanced wound care, ostomy care, continence and critical care, and infusion therapies. In wound care, the company offers solutions designed to promote healing and manage complex wounds such as diabetic foot ulcers, pressure ulcers and surgical sites. These products, often based on specialized dressings and moisture management technologies, are used in hospitals, specialized clinics and home-care settings worldwide.

ConvaTec stock and price level

As of September 3, 2026, ConvaTec Group stock is trading on the London Stock Exchange at about 2.34 pounds per share, with the valuation commentary from Simply Wall St indicating that this level sits well below a modeled fair value of 4.28 pounds. For investors following UK healthcare and medical technology names, this price-to-value gap and the moderate buy consensus underline why the stock remains part of broader discussions about value opportunities in the sector.